Johnson & Johnson CEO Alex Gorsky emphasized his company’s commitment to developing technology for robotic-assisted surgery during the company’s 2019 fourth-quarter earnings call on 22 January.
J&J is late to the robotic-assisted surgery market, but the health-care giant has made a series of acquisitions in robotic-assisted surgery technologies – which it calls digital surgery – and robotic-assisted surgery is a major reason why its research and development budget grew 5.4% to $11.35bn in 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?